Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.5 USD | +4.19% | +0.95% | -30.67% |
05-31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
05-24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.67% | 4.83B | |
+1.22% | 90.59B | |
0.00% | 38.99B | |
-8.52% | 34.09B | |
+64.13% | 26.38B | |
-17.37% | 15.02B | |
-5.99% | 13.17B | |
-10.69% | 11.88B | |
-47.78% | 10.65B | |
+8.09% | 9.25B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals : JPMorgan Adjusts Apellis Pharmaceuticals' Price Target to $57 from $101, Keeps Overweight Rating